Hot issues
The FDA and Novo Nordisk are warning the public about counterfeit Ozempic injections circulating in the U.S. drug supply chain. The falsified products, labeled with lot number PAR0362 and serial numbers beginning with 51746517, were seized by the FDA on April 9, 2025. Their contents and safety are unverified and pose serious health risks.
PSM is seeking input on developing a set of best practices to reduce sales of counterfeit and diverted medicines on online pharmacy-to-pharmacy marketplaces.
The FDA announced that it had seized counterfeit Ozempic injections on April 9. PSM testified at a congressional hearing.
A study examined the 130 enforcement actions undertaken by the U.S. Food and Drug Administration’s Office of Criminal Investigations from 2016 through 2021.
The state of Colorado submitted a revised application to the U.S. Food and Drug Administration to operation a Canadian drug importation plan in March. This blog post examines how the state’s application has changed over the years.
A March 12, 2025 memo said the state had paid more than $150,000 defending itself in a lawsuit Amgen had filed over plans to set an upper payment limit on its rheumatoid arthritis treatment, Enbrel.
Senator Jim Banks asked pointed questions about how FDA will stem the tide of semaglutide and tirzepatide coming from unknown facilities.
Our podcast covers the latest in pharma crime and medicine safety.
Like your information on video? Subscribe to our YouTube playlist!
How is unapproved semaglutide and tirzapetide getting into the US?
Why should fake drugs overseas matter to me? Watch.
Click the images below to see more recent videos.